|
**Overview**: ANCA Reflex MPO PR3 Panel**Introduction**: The ANCA Reflex MPO PR3 Panel is a diagnostic tool designed to confirm ANCA-positive vasculitis using serum samples. In India, AAV prevalence is 10-20 per million, with MPO/PR3 antibodies key for microscopic polyangiitis and granulomatosis with polyangiitis. Reflex testing after positive IFA improves specificity. Symptoms include renal failure, pulmonary hemorrhage, sinusitis. High morbidity from underdiagnosis in rural areas and overlap with TB. Per immunology practices aligned with ICMR guidelines, the test employs immunofluorescence and immunoassay for confirmation over 1-2 days with high specificity, valuable for subtype classification and therapy guidance. This diagnostic falls under autoimmune screening and targets ANCA-positive patients, addressing accurate confirmation to guide treatment. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise management and reducing organ damage. Its serum-based approach ensures reliable detection.**Other Names**: ANCA Reflex Pnl.**FDA Status**: FDA approved, CLIA certified for immunology, compliant with 2025 standards.**Historical Milestone**: Reflex strategy for specificity; in India, used in vasculitis clinics.**Purpose**: The test confirms 4 parameters including c-ANCA to guide vasculitis subtype, inform immunosuppressive therapy.**Test Parameters**: 1. c-ANCA, 2. p-ANCA, 3. MPO-ANCA, 4. PR3-ANCA.**Pretest Condition**: No fasting required; patients should report vasculitis symptoms or positive ANCA IFA.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on renal/pulmonary symptoms, prior ANCA results, infections.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated vasculitis, benefits of confirmation, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunofluorescence and immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or infections can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive MPO/PR3 indicates specific vasculitis, necessitating treatment escalation. Negative may require follow-up.**Specialist Consultation**: Rheumatologists or nephrologists should be consulted for management.**Additional Supporting Tests**: Biopsy or urine analysis for confirmation.**Test Limitations**: May miss atypical cases; comprehensive approach required.**References**: Indian Journal of Rheumatology 2024, Vasculitis Studies India 2023. |
